| 1. |
|
|
| 2. |
- Bauer, HCF, et al.
(författare)
-
The Scandinavian Sarcoma Group Register
- 1999
-
Ingår i: Acta orthopaedica Scandinavica. Supplementum. - : Medical Journals Sweden AB. - 0300-8827 .- 0001-6470. ; 70285, s. 41-44, s. 41-44
-
Tidskriftsartikel (refereegranskat)
|
|
| 3. |
- de, Laverny P, et al.
(författare)
-
EROS variable stars: discovery of a slow nova in the SMC
- 1998
-
Ingår i: ASTRONOMY AND ASTROPHYSICS. - : SPRINGER VERLAG. ; 335:3
-
Annan publikation (övrigt vetenskapligt/konstnärligt)abstract
- We report the discovery of a slow nova found in the core of the Small Magellanic Cloud by the EROS microlensing survey. Nova SMC 1994 is a classical nova with a DQ Her type lightcurve characterized by a deep minimum. Low amplitude variations occurring on
|
|
| 4. |
- Juniper, E F, et al.
(författare)
-
Asthma quality of life during 1 year of treatment with budesonide with or without formoterol
- 1999
-
Ingår i: European Respiratory Journal. - 1399-3003. ; 14:5, s. 1038-1043
-
Tidskriftsartikel (refereegranskat)abstract
- The Formoterol and Corticosteroids Establishing Therapy (FACET) study has provided the first opportunity to examine the long-term effects of inhaled steroids and long-acting beta2-agonists on asthma-specific quality of life. The objectives of the present study were to: evaluate the effects of long-term (1 yr) formoterol and increasing doses of budesonide on asthma quality of life; 2) to determine whether initial improvements in quality of life are sustained when improvements in clinical indices persist; and 3) to evaluate the long-term relationship between changes in clinical indices and changes in quality of life. Of the 852 asthmatic adults enrolled, 470 from five countries participated in this quality of life evaluation. After a 4-week run-in on 1,600 microg budesonide, patients were randomized to either 200 microg (Bud200) or 800 microg budesonide (Bud800) in combination with either 24 microg formoterol (F) or placebo daily for 1 yr. The Asthma Quality of Life Questionnaire (AQLQ) was completed and conventional clinical indices measured at enrolment and randomization and on seven occasions during the following 12 months. During the run-in, there was an improvement in AQLQ score (changes (delta) in overall score approximately 0.50; p<0.0001). After randomization, there was a further improvement in the Bud800+F group (delta=0.21; p=0.028). One month post-randomization, improvements in all groups stabilized and were sustained throughout the 12 months in a pattern very similar to that observed for the conventional clinical indices. The correlation of individual patient changes in clinical indices and changes in AQLQ score during the 12-month randomized period were weak to moderate (maximum r=0.51). Improvements in quality of life, which were greatest in the 800 microg budesonide plus 24 microg formoterol group, were sustained throughout the 12 months in a similar manner to the clinical indices. Long-term changes in conventional clinical indices cannot be used to predict the effect of treatment on individual patient experience.
|
|
| 5. |
- Tattersfield, A E, et al.
(författare)
-
Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group
- 1999
-
Ingår i: American Journal of Respiratory and Critical Care Medicine. - 1535-4970. ; 160:2, s. 594-599
-
Tidskriftsartikel (refereegranskat)abstract
- The identification, prevention, and prompt treatment of exacerbations are major objectives of asthma management. We looked at change in PEF, symptoms, and use of rescue beta-agonists during the 425 severe exacerbations that occurred during a 12-mo parallel group study (FACET) in which low and high doses of budesonide with and without formoterol were compared in patients with asthma. Oral corticosteroids were prescribed for severe exacerbations, the main study end point, defined as the need for a course of oral corticosteroids (n = 311) or a reduction in morning PEF of > 30% on two consecutive days. PEF, symptoms, and bronchodilator use over the 14 d before and after the exacerbation were obtained from diary cards. Exacerbations were characterized by a gradual fall in PEF over several days, followed by more rapid changes over 2 to 3 d; an increase in symptoms and rescue beta-agonist use occurred in parallel, and both the severity and time course of the changes were similar in all treatment groups. Exacerbations identified by the need for oral corticosteroids were associated with more symptoms and smaller changes in PEF than those identified on the basis of PEF criteria. Female sex was the main patient characteristic associated with an increased risk of having a severe exacerbation. Exacerbations may be characterized predominantly by change in symptoms or change in PEF, but the pattern was not affected by the dose of inhaled corticosteroid or by whether the patient was taking formoterol.
|
|
| 6. |
- Ferrari, D., et al.
(författare)
-
P2Z purinoreceptor ligation induces activation of caspases with distinct roles in apoptotic and necrotic alterations of cell death
- 1999
-
Ingår i: FEBS Letters. - : Elsevier. - 0014-5793 .- 1873-3468. ; 447:1, s. 71-75
-
Tidskriftsartikel (refereegranskat)abstract
- Myeloic cells express a peculiar surface receptor for extracellular ATP, called the P2Z/P2X(7) purinoreceptor, which is involved in cell death signalling. Here, we investigated the role of caspases, a family of proteases implicated in apoptosis and the cytokine secretion. We observed that extracellular ATP induced the activation of multiple caspases including caspase-1, -3 and -8, and subsequent cleavage of the caspase substrates PARP and Iamin B. Using caspase inhibitors, it was found that caspases were specifically involved in ATP-induced apoptotic damage such as chromatin condensation and DNA fragmentation, In contrast, inhibition of caspases only marginally affected necrotic alterations and cell death proceeded normally whether or not nuclear damage was blocked. Our results therefore suggest that the activation of caspases by the P2Z receptor is required for apoptotic but not necrotic alterations of ATP-induced cell death. (C) 1999 Federation of European Biochemical Societies.
|
|
| 7. |
|
|
| 8. |
- Magnusson, P, et al.
(författare)
-
Photometric observations and modeling of asteroid 1620 Geographos
- 1996
-
Ingår i: ICARUS. - : ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS. - 0019-1035. ; 123:1, s. 227-244
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- Photometric observations of 1620 Geographos in 1993 and 1993 are presented and, in combination with previously published data, are used to derive models of Geographos, We estimate that the sidereal period of rotation is 0.21763860 +/- 0.00000003 days (5(h
|
|
| 9. |
|
|
